First malaria vaccine for babies approved for use
Half a million deaths in 2023
In 2023 - the year for which the most recent figures are available - malaria was linked to around 597,000 deaths. Almost all of the deaths were in Africa, and around three quarters of them were children under five years old. Malaria treatments for children do exist but until now, there was none specifically for the very youngest babies and small children, who weigh less than 4.5kg or around 10lb. Instead they have been treated with drugs designed for older children. But that presents risks, as doses for these older children may not be safe for babies, whose liver functions are still developing and whose bodies process medicines differently. Experts say this has led to what is described as a "treatment gap".Now a new medicine, developed by the drug company Novartis, has been approved by the Swiss authorities and is likely to be rolled out in regions and countries with the highest rates of malaria within weeks. Novartis is planning to introduce it on a largely not-for-profit basis.
The smallest and most vulnerable
The company's chief executive, Vas Narasimhan, says this is an important moment."For more than three decades, we have stayed the course in the fight against malaria, working relentlessly to deliver scientific breakthroughs where they are needed most."Together with our partners, we are proud to have gone further to develop the first clinically proven malaria treatment for newborns and young babies, ensuring even the smallest and most vulnerable can finally receive the care they deserve."The drug, known as Coartem Baby or Riamet Baby in some countries, was developed by Novartis in collaboration with the Medicines for Malaria Venture (MMV), a Swiss-based not-for-profit organisation initially backed by the British, Swiss and Dutch Governments, as well as the World Bank and the Rockefeller Foundation.Eight African nations also took part in the assessment and trials of the drug and they are expected to be among the first to access it.Martin Fitchet, CEO of MMV, says this is another important step on the road towards ending the huge toll taken by malaria."Malaria is one of the world's deadliest diseases, particularly among children. But with the right resources and focus, it can be eliminated."The approval of Coartem Baby provides a necessary medicine with an optimised dose to treat an otherwise neglected group of patients and offers a valuable addition to the antimalarial toolbox."Dr Marvelle Brown, associate professor at the University of Hertfordshire's School of Health, Medicine and Life Sciences, says this should be seen as a major breakthrough in saving the lives of babies and young children."The death rate for malarial infections, particularly in sub-Saharan Africa is extremely high - over 76% of deaths occur in children under five years old."Increase in death from malaria is further compounded in babies born with sickle cell disease, primarily due to a weak immune system."From a public health perspective, Novartis making this not-for-profit can help with reducing inequality in access to healthcare."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
3 hours ago
- The Independent
Why women are at higher risk of having Alzheimer's than men
Wo men are twice as likely as men to develop Alzheimer's disease, accounting for almost two-thirds of American sufferers. Scientists are investigating two primary biological differences: chromosomal variations, particularly genes on the X chromosome. The natural decline of reproductive hormones during menopause is also considered a significant factor contributing to women 's increased risk. Research suggests that women who received hormone replacement therapy after age 70 exhibited higher levels of the Alzheimer's hallmark protein 'tau' and greater cognitive decline. Further studies are required to fully comprehend the complex associations between menopause, hormonal changes, and the long-term risk of developing Alzheimer's.
The Independent
4 hours ago
- The Independent
Weight loss jabs not enough to tackle obesity, leading medics warn
Weight loss injections will not be enough to make 'lasting progress' in tackling the obesity epidemic, leading medical experts have warned. The Royal College of Physicians (RCP) called on the government to ensure equitable access to weight management services across the country and stressed the importance of wraparound support to prevent individuals from regaining weight after initial loss. The RCP also called for action to tackle the nation's 'broken food system' to help people make healthier choices, including reducing 'aggressive' marketing and advertising of unhealthy food. 'Medication alone will not be enough to make meaningful and lasting progress on tackling obesity,' the College said in a new position statement, adding that the government must also tackle the 'social and environmental drivers of obesity'. 'Policies should reduce aggressive marketing and advertising of foods high in fat, salt, and sugar, while increasing the availability and affordability of healthy foods from an early age. 'We must tackle our broken food system and ensure it is easier for all to choose to eat healthily.' Last week the Government pledged to 'launch a moonshot to end the obesity epidemic' in its 10 Year Plan for Health. Now the College has urged ministers to set out details and timelines of how it will deliver this commitment. It comes as the College released a poll of members and fellows, showing that four in five (80 per cent) of almost 19,000 doctors in the UK, surveyed by the RCP, said that the number of patients they see with obesity has increased over the last five years. The RCP warned that treatment for other illnesses is less effective as a result of obesity. Dr Kath McCullough, special adviser on obesity for the RCP, said: 'The narrative that obesity is about personal responsibility or that new medications will solve the problem is misleading. 'Obesity is a chronic illness shaped by a range of factors and influences – and it's on the rise. 'We are seeing daily how obesity causes and makes it harder to treat conditions, from diabetes and arthritis to heart disease and cancer. ' The NHS 10 Year Plan rightly sets out a suite of measures that can be used in the fight against obesity, but the armoury is far from complete. 'Weight loss drugs can be part of the solution for some patients, but our efforts must focus on preventing people developing obesity and overweight in the first place. 'We welcome the measures Government announced last week – they have great potential. We look forward to seeing the detail on how we will translate that ambition into reality.' RCP president Dr Mumtaz Patel said: 'Doctors are telling us loud and clear about the scale and impacts of obesity. It is undermining treatment, driving up complications and placing additional pressure on an already overwhelmed NHS. 'In less affluent communities, we're watching obesity fuel a vicious cycle – people are getting sicker, their care becomes harder to deliver and the system just can't catch up. 'We welcome steps the Government is taking. No few individual measures will be enough. It is a complex problem that requires multifaceted solutions. 'We need bold, joined-up preventative action that tackles the genetic, social, economic and commercial factors that drive obesity.' Around 29 per cent of adults in the UK are obese, and an estimated 1.5 million are taking weight loss jabs in the UK.
The Independent
4 hours ago
- The Independent
New ‘sponge' cancer test to be trialled in high-street pharmacies
Hundreds of people experiencing persistent heartburn or acid reflux will soon be offered a ' sponge on a string ' test in high-street pharmacies. NHS England is piloting a new way of preventing oesophageal cancer by identifying individuals with a condition called Barrett's oesophagus, which occurs when stomach acid damages the lining of the oesophagus or food pipe. Some cells may grow abnormally and then develop into oesophageal cancer. From early next year, around 1,500 people in London and the East Midlands will participate in these new "heartburn health checks" to test for Barrett's oesophagus. During the test, the patient swallows a small capsule attached to a string. The capsule dissolves in the stomach and leaves a small sponge about the size of a 1p coin. The sponge is then pulled out via the string by NHS staff after a few minutes, during which time it collects cells from the oesophageal lining for analysis in the lab. This test is already used in hospitals and community diagnostic centres to help reduce the need for invasive endoscopies in Barrett's patients. During the pilot, pharmacists will work to spot patients who are regularly using over-the-counter medicines to ease their heartburn but who have not sought help from their GP. The pilot will run for two years before potentially being rolled out more widely. Professor Peter Johnson, NHS national cancer director, said the 'new pilot brings a convenient test to where people shop, making it easier than ever for patients to check signs and symptoms that might be worrying them'. 'For the majority of people with persistent reflux, these quick and easy heartburn health checks will provide peace of mind that you aren't at increased risk of cancer, and for those who do find out they have Barrett's oesophagus, regular follow-up checks will be put in place so any further cell changes can be spotted early.' If pre-cancerous cells are found, treatment can be offered to remove the cells through endoscopy or a procedure known as radiofrequency ablation. Of almost 10,000 patients diagnosed with oesophageal cancer in the UK each year, 80 per cent are diagnosed at a late stage. Only one in five people survive a year, meaning early diagnosis is crucial. Eddie, aged 77 from Suffolk, says the test may have saved his life after years of persistent heartburn. He said: 'It used to wake me up at night, but I always thought it was just one of those things. 'To think that something as simple as swallowing a capsule could uncover a hidden risk is truly remarkable. 'The test was quick, straightforward, and completely changed how I think about my health. 'Knowing I have Barrett's oesophagus meant I was prioritised, my condition was monitored, and as a result, my dysplasia (cell changes) was caught early. Main symptoms of oesophageal cancer NHS 'I am now able to get targeted treatment to stop my condition progressing to cancer, rather than finding out when it's too late. 'This never would have been caught if it wasn't for capsule sponge testing. This test gave me peace of mind and access to early treatment and could mean the difference between life and death for so many others.' The NHS has partnered with Boots and diagnostics company Cyted Health for the pilot, alongside Heartburn Cancer UK. Public health minister Ashley Dalton said: 'Last week, as part of our 10-year health plan, we promised a neighbourhood health service – convenient care nearer to where people live. 'Today's announcement is a fantastic example of the life-saving potential of healthcare on your high street. 'Being able to spot the warning signs using a 10-minute test in a local pharmacy – before cancer has even taken hold – will be a game-changer. 'As part of our Plan for Change to tackle the biggest killers, this government is committed to back innovation and make our NHS fit for the future to drive up this country's cancer survival rates.'
